1、Trial sites are under unsustainable pressure.Five steps can help pharma companies provide relief while building competitive advantage.By Jackie Flanagan and Jason EversHow Customer-First Clinical Trials Cut Complexity and DelaysCopyright 2023 Bain&Company,Inc.All rights reserved.1How Customer-First

2、Clinical Trials Cut Complexity and DelaysAt a Glance Rapid innovation has had the unintended consequence of burgeoning complexity for clinical trial sites,with 56%reporting that complexity has increased from three years ago,according to a Bain survey.Today,53%of sites say they lack the bandwidth to

3、run trials,up from 14%before the pandemic.Piecemeal trial solutions promise improvements that are misaligned with sites actual experience.With five principles,pharma companies can design next-gen trials that reduce delays,build competitive advantage,and bring critical innovation to patients.A new dr

4、ugs mechanism-of-action exclusivity often lasts only half as long as in the early 2000s,fueling pharmaceutical stakeholders calls for accelerated trial timelines.Capture rates are now staggering,often representing 10%to 20%of all patients.At the same time,53%of clinical trial sites say they have ins

5、ufficient bandwidth to support their current phase 2 or 3 trials,according to a Bain survey.And 56%say complexity has increased from just three years ago(see Figure 1).Behind that complexity is a surge of immense potential.Innovation and breakthrough designations are on the rise.FDA approvals nearly

6、 doubled between 2010 and 2020,including those in critical cell and gene therapies.Pharma companies are pursuing narrower and more specific indications with increasingly complex drugs,promising relief to patientsif sites can carry out more and more complicated trials.Beyond scientific complexity,ope